Sudeep Pharma's Nandesari Plant in Gujarat Clears US FDA Review
Sudeep Pharma's US FDA-approved Nandesari plant in Gujarat adds 51,200 MT annual capacity for pharma, food & nutrition, with supplies targeted from H2 FY27
Research Desk
Sudeep Pharma Limited has confirmed that the US Food and Drug Administration has cleared its greenfield plant at 179 Nandesari in Gujarat, permitting manufacturing to begin at the site. The plant carries an installed annual capacity of 51,200 metric tonnes. Sudeep Pharma stated that the site is designed to serve demand in the pharmaceutical, food, and nutrition industries, with commercial supplies planned for the second half of fiscal year 2027 once customer qualification work is finished.
How the New Capacity Will Be Deployed
Of the total 51,200 MT, roughly 60 percent is earmarked for the company's current Pharma and Food & Nutrition portfolios. The balance will go toward newer categories: phosphates, glycinates, gluconates, and citrates.
The design also allows for high-value ingredients and new-age molecules, among them bisglycinates. The company said this feature will broaden its product range and deepen its footprint in regulated markets. The added capacity is expected to bolster operations across its three core segments, Pharma, Food & Nutrition, and Specialty Ingredients, and help the company serve growing demand in India and abroad.
Leadership Response to the Clearance
Sujit Bhayani, the company's managing director, said the FDA approval for the 179 Nandesari greenfield facility is an important milestone in its growth journey, enabling manufacturing to commence and unlocking significant additional capacity.
He added that it strengthens the company's ability to serve a wider customer base across pharmaceutical, food, and nutrition segments in India and international markets. With the clearance in hand, Sudeep Pharma said it will now move to speed up customer qualification processes and audits at the Nandesari site ahead of the targeted H2 FY27 start of supplies.
Company Background
Sudeep Pharma Limited manufactures pharmaceutical excipients, food and nutrition ingredients, and specialty mineral-based solutions for customers worldwide. The company traces its roots to mineral chemistry and manufacturing expertise and emphasizes innovation, value-added products, and growth of its global presence.
Tracked in the database
US FDA Approval of Greenfield Pharma Plant · Asia-Pacific
US FDA Approval of Greenfield Pharma Plant
Asia-Pacific
Industrial
26 October 2026
2 min read
Tagged
Also read
Tillotts Pharma Plans $25.7 Million Investment to Acquire Haupt Pharma Wülfing in Gronau, Germany
Kier Resumes Pre-Construction Work on $4.70 Billion H50 High-Containment Facility in Harlow, UK
Idorsia Advances Daridorexant Into Autism Research After Phase 2 Trial Reveals Unexpected Functional Benefits in Switzerland
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.